Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00480662
NCT00480662
Completed
Phase 3

A 6-Month, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Alendronate 280-mg Oral Buffered Solution Once Weekly in Patients With Paget's Disease of Bone

Organon and Co0 sites60 target enrollmentOctober 2001
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPaget's Disease of Bone

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Paget's Disease of Bone
Sponsor
Organon and Co
Enrollment
60
Primary Endpoint
Patients will have a decrease of at least 30% in their blood alkaline phosphatase level after 6 months
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.

Registry
clinicaltrials.gov
Start Date
October 2001
End Date
October 2002
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Male or female, ages 18 to 90 years with a diagnosis of Paget's bone disease

Exclusion Criteria

  • •Patient cannot stand or sit upright for at least 30 minutes
  • •Patient has difficulty swallowing or problems with digestive system

Outcomes

Primary Outcomes

Patients will have a decrease of at least 30% in their blood alkaline phosphatase level after 6 months

Secondary Outcomes

  • MK0217 will be safely tolerated

Similar Trials

Completed
Phase 3
A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)Osteoporosis
NCT00480766Organon and Co173
Completed
Phase 2
A Study to Assess the Safety and Efficacy of an Investigational Drug (MK-686) in Patients With Osteoarthritis (0686-006)Osteoarthritis
NCT00296569Merck Sharp & Dohme LLC150
Terminated
Phase 2
Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)Alzheimer's Disease
NCT01852110Merck Sharp & Dohme LLC240
Completed
Phase 2
MK3207 for Treatment of Acute Migraines (3207-005)Migraine
NCT00712725Merck Sharp & Dohme LLC676
Completed
Phase 1
A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)Osteoporosis
NCT00770159Merck Sharp & Dohme LLC78